No Data
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Featured announcements | Kanzhun revenue increased 19% year-on-year in the third quarter; China Taibao's original premium income during the year exceeded 410 billion yuan
Xinyi Glass and Xinyi Auto Glass (Hong Kong) signed a 2024 glass supply agreement; CGN Energy completed a cumulative total of 17,684.1 gigawatt-hours of power generation in the first 11 months, an increase of 1.7% over the previous year.
IMMUNOTECH-B (06978.HK): CAR-T-19 injection has been granted breakthrough therapy designation.
On December 11, Gelonghui announced that IMMUNOTECH-B (06978.HK) has released a statement indicating that the group's product CAR-T–19 injection (a type of anti-CD19 single-chain antibody chimeric antigen receptor T cell injection) has been granted breakthrough therapy designation by the National Medical Products Administration's Drug Evaluation Center for the treatment of patients aged 25 and younger with relapsed/refractory B-cell acute lymphoblastic leukemia ("B-ALL"). This designation is based on reliable clinical efficacy and safety data for CAR-T–19 injection. It will expedite the clinical development of CAR-T–19 injection and accelerate its availability for patients.
Express News | Immunotech Biopharm - CAR-T-19 Injection Granted Breakthrough-Therapy Designation by Nmpa China
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
